Aspirin Therapy for Testosterone-Induced Erythrocytosis

Pathophysiology and Risk Assessment

Testosterone therapy can lead to hemoconcentration with elevated hemoglobin levels, increasing blood viscosity and potentially raising thrombotic risk 3
The primary management of testosterone-induced erythrocytosis should focus on maintaining hematocrit below 45% through phlebotomy rather than relying solely on antiplatelet therapy 1, 2
High platelet reactivity in patients with elevated hematocrit can increase thrombotic risk 2-4 fold, which may be partially mitigated by aspirin therapy 4, 5

If testosterone-induced erythrocytosis resembles polycythemia vera (PV) features, low-dose aspirin (81-100 mg daily) plus phlebotomy to maintain hematocrit <45% is recommended, as suggested by the National Comprehensive Cancer Network 1, 2
For patients with both elevated hemoglobin and thrombocytosis (resembling essential thrombocythemia), aspirin may reduce thrombotic risk, particularly in those with JAK2 mutations 2
In patients with testosterone-induced erythrocytosis AND established cardiovascular disease or multiple risk factors, low-dose aspirin may provide modest benefit in reducing stroke risk, according to the American Heart Association 3, 6
The American Diabetes Association notes that the ASCEND trial showed a 12% reduction in vascular events with aspirin in high-risk patients, though with increased bleeding risk 6

If aspirin is indicated, the lowest effective dose (81-100 mg daily) should be used to minimize bleeding risk, as recommended by the American College of Chest Physicians 5, 7, 8
Higher doses of aspirin (>100 mg) have not demonstrated improved efficacy but do increase bleeding risk 5, 8

Monitor for signs of bleeding, particularly gastrointestinal bleeding, which occurs at higher rates with aspirin use, as cautioned by the American Diabetes Association 6, 8
Regularly assess hematocrit levels and consider phlebotomy as the primary intervention when hematocrit exceeds 45%, as advised by the National Comprehensive Cancer Network 1, 2
In patients with platelet counts >1,000×10^9/L, aspirin should be used with caution due to potential acquired von Willebrand syndrome and increased bleeding risk, as warned by the National Comprehensive Cancer Network 2